Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 236

1.

CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load.

Miller V, Staszewski S, Sabin C, Carlebach A, Rottmann C, Weidmann E, Rabenau H, Hill A, Lepri AC, Phillips AN.

J Infect Dis. 1999 Aug;180(2):530-3.

2.

Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.

Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, Abrams DI, Kitahata MM, Krone M, Neilands TB, Brand RJ, Lederman MM, Martin JN.

AIDS. 2003 Sep 5;17(13):1907-15.

PMID:
12960823
3.
4.

"Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy.

Wood E, Hogg RS, Yip B, Tyndall MW, Sherlock CH, Harrigan RP, O'Shaughnessy MV, Montaner JS.

J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):159-66.

PMID:
12045678
5.

HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.

Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.

AIDS. 2008 Aug 20;22(13):1583-8. doi: 10.1097/QAD.0b013e328305bd77.

PMID:
18670217
6.

Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy.

Yokozaki S, Takamatsu J, Nakano I, Katano Y, Toyoda H, Hayashi K, Hayakawa T, Fukuda Y.

Blood. 2000 Dec 15;96(13):4293-9.

7.

Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy.

Mocroft A, Phillips AN, Ledergerber B, Smith C, Bogner JR, Lacombe K, Wiercinska-Drapalo A, Reiss P, Kirk O, Lundgren JD; EuroSIDA Study Group.

Antivir Ther. 2010;15(4):563-70. doi: 10.3851/IMP1559.

PMID:
20587849
8.

The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml.

Easterbrook PJ, Ives N, Waters A, Mullen J, O'Shea S, Peters B, Gazzard BG.

AIDS. 2002 Jul 26;16(11):1521-7.

PMID:
12131190
9.

Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy.

Abgrall S, Duval X, Joly V, Descamps D, Matheron S, Costagliola D; Clinical Epidemiology Group from the French Hospital Database on HIV.

Clin Infect Dis. 2003 Dec 1;37(11):1517-26. Epub 2003 Oct 29.

10.

Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression.

Phillips AN, Staszewski S, Lampe F, Youle MS, Klauke S, Bickel M, Sabin CA, Doerr HW, Johnson MA, Loveday C, Miller V; Royal Free Centre for HIV Medicine; Goethe Universität Clinic Cohort.

J Infect Dis. 2002 Oct 15;186(8):1086-91. Epub 2002 Sep 30.

11.

Modeling the time course of CD4 T-lymphocyte counts according to the level of virologic rebound in HIV-1-infected patients on highly active antiretroviral therapy.

Kousignian I, Abgrall S, Duval X, Descamps D, Matheron S, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV.

J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):50-7.

PMID:
14501793
12.
13.

Effect of persistent moderate viremia on disease progression during HIV therapy.

Raffanti SP, Fusco JS, Sherrill BH, Hansen NI, Justice AC, D'Aquila R, Mangialardi WJ, Fusco GP; Collaborations in HIV Outcomes Research/United States Project.

J Acquir Immune Defic Syndr. 2004 Sep 1;37(1):1147-54.

PMID:
15319674
14.

Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers.

Ostrowski SR, Katzenstein TL, Pedersen BK, Gerstoft J, Ullum H.

Scand J Immunol. 2008 Dec;68(6):652-60. doi: 10.1111/j.1365-3083.2008.02184.x.

15.

Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.

Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S; QUEST Study Group.

Clin Infect Dis. 2007 Aug 1;45(3):381-90. Epub 2007 Jun 26.

16.

Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.

García F, Plana M, Vidal C, Cruceta A, O'Brien WA, Pantaleo G, Pumarola T, Gallart T, Miró JM, Gatell JM.

AIDS. 1999 Jul 30;13(11):F79-86.

PMID:
10449278
17.

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group; Italian Cohort Naive for Antiretrovirals Study Group.

Clin Infect Dis. 2005 Jun 15;40(12):e101-9. Epub 2005 May 5.

18.

Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.

Bedell R, Heath KV, Hogg RS, Wood E, Press N, Yip B, O'Shaughnessy MV, Montaner JS.

Antivir Ther. 2003 Oct;8(5):379-84.

PMID:
14640384
19.

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

AIDS. 1999 Dec 3;13(17):2377-88.

PMID:
10597779
20.

Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy.

Skowron G, Street JC, Obee EM.

J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):313-9.

PMID:
11707666
Items per page

Supplemental Content

Write to the Help Desk